Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Australian Consumer Sentiment Slumps in Early December as Inflation Fears Resurface 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Global Markets Slide as Tech Stocks Sink, Yields Rise, and AI Concerns Deepen 
Gold Prices Slip Slightly in Asia as Silver Nears Record Highs on Dovish Fed Outlook 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
China’s November Economic Data Signals Slowing Industrial Output and Weak Consumer Demand 
China’s Small Bank Consolidation Struggles as Profits Fall and Risks Persist 
Asian Currencies Trade Sideways as Dollar Weakens Ahead of Key U.S. Data 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Bausch + Lomb announces a $1.75 billion definitive agreement with Novartis to acquire XIIDRA dry eye treatment, positioning the Ontario-based eye health company as a leader in ocular surface diseases and bolstering its prescription dry eye unit.
With the purchase, Bausch + Lomb will have a considerable opportunity to grow its prescription dry eye unit further. Novartis AG is divesting its XIIDRA dry-eye treatment to the Swiss drugmaker, and the transaction value could go up to $2.5 billion with a $1.75 billion upfront payment.
In any case, Novartis acquired the XIIDRA product from Takeda for $3.4 billion in 2019. Pharmastar reported that under the helm of leadership of chief executive officer Vas Narasimhan, Novartis has been expanding the company by spinning off some of the low-growth business units, such as its Alcon eye care. It has plans to do the same for its Sandoz healthcare company subsidiary.
“This acquisition is a prime example of our strategy in action, as it provides needed scale for the company and transforms our pharmaceuticals business by making us a leader in ocular surface diseases,” Bausch + Lomb’s chairman and CEO, Brent Saunders, said in a press release. “The deal is also expected to accelerate margin expansion through a larger mix of pharmaceutical products in our portfolio, provide strong and immediate earnings accretion and presents a clear path to deleverage, making it financially compelling.”
Marguerite McDonald, M.D., F.A.C.S., OCLI Vision at Oceanside, N.Y., also explained that “Dry eye disease is multi-factorial and can stem from varying root causes, which means differing treatment options are needed. With the acquisition of XIIDRA and the recent approval of MIEBO, Bausch + Lomb enhances its approach to different facets of dry eye and is well positioned to ensure both medicines reach as many patients as possible.”
Photo by: Bausch & Lomb Website
